LETTER TO THE EDITOR
Increased risk of bleeding with the use of tipranavir boosted with ritonavir in haemophilic patients
C. ARBUTHNOT,
C. ARBUTHNOT
University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, West Midlands, UK
Search for more papers by this author J. T. WILDE,
J. T. WILDE
University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, West Midlands, UK
Search for more papers by this author
C. ARBUTHNOT,
C. ARBUTHNOT
University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, West Midlands, UK
Search for more papers by this author J. T. WILDE,
J. T. WILDE
University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, West Midlands, UK
Search for more papers by this author
First published: 31 August 2007
No abstract is available for this article.
References
- 1
Racoosin JA,
Kessler CM.
Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series.
Haemophilia
1999; 5: 266–9.
- 2
Wilde JT.
Protease inhibitor therapy and bleeding.
Haemophilia
2000; 6: 487–90.
- 3
Yazdanpanah Y,
Viget N,
Cheret A
et al.
Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir–ritonavir.
AIDS
2003; 17: 2397–9.
- 4
Rusconi S,
La Seta Catamancio S, Citterio et al. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
Antimicrob Agents Chemother
2000; 44: 1328–32.
- 5
Ryan CT.
New black box warning for ritonavir–boosted tipranavir.
AIDS Clin Care, 2006; 18: 72.
